NCT05176314View on ClinicalTrials.gov

A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LY3527727) and Rosuvastatin in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 11, 2022

Primary Completion Date

April 20, 2022

Study Completion Date

April 20, 2022

Conditions
Healthy
Interventions
DRUG

Rosuvastatin

Administered Orally.

DRUG

Pirtobrutinib

Administered Orally.

Trial Locations (2)

65802

QPS Bio-Kinetic Clinical Applications, Springfield

75247

Covance Dallas, Dallas

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Loxo Oncology, Inc.

INDUSTRY

NCT05176314 - A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LY3527727) and Rosuvastatin in Healthy Participants | Biotech Hunter | Biotech Hunter